Skip to main content

Table 4 Disutility, incremental mortality, and costs for the first year and subsequent years after fracture and diabetes

From: Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

  Fracture Diabetes
Age 1st year Subsequent years 1st year Subsequent years
Disutility by age group
40-44 -0.0833 -0.0293 -0.000179 -0.000333
45-49 -0.0971 -0.0324 -0.000173 -0.000247
50-54 -0.1047 -0.0349 -0.000160 -0.000263
55-59 -0.1068 -0.0371 -0.000074 -0.000681
60-64 -0.1094 -0.0391 -0.000040 -0.000727
65-69 -0.1113 -0.0412 -0.000003 -0.000618
70+ -0.1212 -0.0425 -0.000128 -0.000754
Incremental mortality by age group
40-44 0.0092 0.0001 0.000390 0.000320
45-49 0.0115 0.0001 0.000715 0.000285
50-54 0.0127 0.0001 0.000875 0.000685
55-59 0.0142 0.0002 0.001160 0.000320
60-64 0.0187 0.0003 0.001525 0.000755
65-69 0.0260 0.0006 0.002025 0.001035
70+ 0.0541 0.0018 0.002645 0.000850
Costs by age group
40-44 $3,926 $63 $12 $24
45-49 $4,643 $68 $13 $32
50-54 $5,041 $73 $16 $55
55-59 $5,159 $78 $21 $93
60-64 $5,302 $83 $24 $151
65-69 $7,901 $87 $25 $260
70+ $10,880 $744 $27 $341